Collects and stores tissue and blood from people with gastrointestinal cancers

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a stomach, food pipe, pancreas, liver, bile duct, anal or bowel cancer, or related tumours, who need surgery or a biopsy. Tissue and blood samples are stored for research.

Sex

All sexes can join.

Disease stage

Stomach, esophageal, pancreas, liver, biliary, anal or colorectal cancer, gastrointestinal stromal tumor, peritoneal mesothelioma or neuroendocrine tumor.

The registry criteria, word for word

What the trial wants to find out

The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer, an estimated 50 to 100 of each tumor type. To collect and store blood samples from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer. To create a database for the collected tissue and allow access to relevant clinical information for current and future protocols. To create tissue microarrays for each gastrointestinal cancer subtype, namely, gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer, to facilitate future molecular studies. To grant access to Dr Kindler, Dr. Salgia, and Dr. Catenacci to this database (as it is being acquired) of the coupled patient tissue samples (normal and malignant) and relevant clinical information for the investigation of tyrosine kinases, such as Met and Ron, receptor tyrosine kinase family members, STATs, paxillin, focal adhesion proteins, cell motility/migration proteins, tyrosine/serine/threonine kinase family members, related molecules, and downstream targets implicated in the pathogenesis of GI cancers. Examples of molecular testing include evaluation of DNA mutation, alternative splice variants, protein expression and phosphorylation, and immunohistochemistry on samples. These studies will be correlated with clinical information as stated above.

The 10 groups in the trial

• Gastric Cancer
• Gastrointestinal Stromal Tumors (GIST)
• Esophageal Cancer
• Pancreas Cancer
• Hepatocellular Cancer
• Biliary Cancer
• Neuroendocrine Cancer
• Peritoneal Mesothelioma
• Anal Cancer
• Colorectal Cancer